Abstract
Glycopeptide antibiotics are a class of agents, composed of glycosylated cyclic or polycyclic peptides. Clinically useful glycopeptides include vancomycin, teicoplanin, dalavancin, and telavancin.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsFurther Reading
Arias, C. A., Contreras, G. A., & Murray, B. E. (2010). Management of Multi-Drug Resistant Enterococcal Infections. Clin Microbiol Infect.
Credito, K. L., & Appelbaum, P. C. (2004). Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother, 48(11), 4430–4434.
Curcio, D. (2010). Resistant pathogen-associated skin and skin-structure infections: antibiotic options. Expert Rev Anti Infect Ther, 8(9), 1019–1036.
Dificid® oral tablets [package insert]. San Diego, CA: Optimer Pharmaceuticals Inc, April, 2011.
Di Paolo, A., Malacarne, P., Guidotti, E., Danesi, R., & Del Tacca, M. (2010). Pharmacological issues of linezolid: an updated critical review. Clin Pharmacokinet, 49(7), 439–447.
Guskey, M. T., & Tsuji, B. T. (2010). A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacotherapy, 30(1), 80–94.
Kollef, M. H. (2009). New antimicrobial agents for methicillin-resistant Staphylococcus aureus. Crit Care Resusc, 11(4), 282–286.
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., et al. (2011). Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis, 52(3), 285–292.
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., et al. (2011). Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med, 364(5), 422–431.
Nailor, M. D., & Sobel, J. D. (2009). Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. Infect Dis Clin North Am, 23(4), 965–982, ix.
Pfeiffer, R. R. (1981). Structural features of vancomycin. Rev Infect Dis, 3 suppl, S205-209.
Rybak, M. J. (2006). The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Clin Microbiol Infect, 12 Suppl 1, 24–32.
Saravolatz, L. D., Stein, G. E., & Johnson, L. B. (2009). Telavancin: a novel lipoglycopeptide. Clin Infect Dis, 49(12), 1908–1914.
Sullivan, K. M., & Spooner, L. M. (2010). Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection. Ann Pharmacother, 44(2), 352–359.
Welte, T., & Pletz, M. W. (2010). Antimicrobial treatment of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. Int J Antimicrob Agents, 36(5), 391–400.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Finberg, R.W., Guharoy, R. (2012). Glycopeptides and Other Agents Used to Treat Gram-Positive Cocci. In: Clinical Use of Anti-infective Agents. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-1068-3_8
Download citation
DOI: https://doi.org/10.1007/978-1-4614-1068-3_8
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-1067-6
Online ISBN: 978-1-4614-1068-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)